<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00124150</url>
  </required_header>
  <id_info>
    <org_study_id>IMASH trial</org_study_id>
    <nct_id>NCT00124150</nct_id>
  </id_info>
  <brief_title>Intravenous Magnesium Sulfate in Aneurysmal Subarachnoid Haemorrhage (IMASH)</brief_title>
  <official_title>Phase 3 Study (Multi-center, Randomized Controlled Clinical Trial) of Intravenous Magnesium Sulfate to Improve Outcome After Aneurysmal Subarachnoid Haemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The IMASH trial is a simple, randomized, double-blinded, placebo-controlled, multi-center
      trial to answer the question: &quot;Does intravenous magnesium sulfate improve clinical outcome
      after aneurysmal subarachnoid hemorrhage?&quot;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vasospasm worsen outcome in patients with aneurysmal subarachnoid hemorrhage (ASAH).

      Magnesium is known to dilate cerebral arteries and to block N-methyl-D-aspartate receptors in
      the injured neurons.

      Intravenous magnesium may prevent vasospasm after subarachnoid hemorrhage and may protect
      neurons against damage during established vasospasm.

      The IMASH trial is a randomized, placebo-controlled, double-blinded, multi-center trial to
      evaluate the effect that intravenous magnesium sulfate infusion on the clinical outcome of
      patients with aneurysmal subarachnoid haemorrhage.

      Methods:

      After obtaining randomisation code:

        -  Start MgSO4 20 mmol over 30 minutes, followed by infusion of 80 mmol/day or equivalent
           volume of saline within 48 h after onset of symptom,

        -  Study drug to be infused for 14 days from the day of hemorrhage (regarded as day 0).

        -  Measure plasma magnesium concentration daily and perform transcranial Doppler to monitor
           blood flow velocities of both middle cerebral arteries and extracranial segment of the
           internal carotid arteries.

        -  Plasma magnesium concentration in the IV MgSO4 group should be raised to 2.0-2.5 mmol/L
           or twice the serum baseline level. Patients that are randomized to saline infusion will
           only have their magnesium levels normalized if there is a clinical indication to do so.

      Outcome assessment Primary outcome: Extended Glasgow Outcome Scale at six months Secondary
      outcome: Incidence of clinical vasospasm, Barthel Index; modified Rankin score, modified
      National Institute of Health Stroke Score, MCA velocities, other major complications

      Study duration:

      6 years with a refined sample size of 340 after analysis of pilot study data; with planned
      interim analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Extended Glasgow Outcome Scale</measure>
    <time_frame>At six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinical vasospasm</measure>
    <time_frame>Within first 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>At six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Score</measure>
    <time_frame>At six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified National Institute of Health Stroke Score</measure>
    <time_frame>At six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other major complications requiring intensive care unit admission</measure>
    <time_frame>During first 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">327</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous magnesium sulfate infusion for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Saline infusion without additional magnesium sulfate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous magnesium sulfate infusion</intervention_name>
    <description>80mg per day</description>
    <arm_group_label>M</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASAH (as indicated by CT scan or lumbar puncture and an intracranial aneurysm
             confirmed by computer tomographic or conventional angiography)

          -  Within 48 hrs of ictus (hemorrhage event)

        Exclusion Criteria:

          -  Pregnancy

          -  Major renal, hepatic or pulmonary disease

          -  Major cardiac disease or recent myocardial infarct (&lt; 6 months)

          -  Age less than 18 years

          -  Moribund condition on admission (defined as a patient that is in such a poor clinical
             condition that further active neurosurgical management would not be anticipated)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wai S Poon, MB ChB FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Surgery, The Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Surgery, The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <zip>852</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.surgery.cuhk.edu.hk/imash-trial/</url>
    <description>IMASH trial homepage</description>
  </link>
  <reference>
    <citation>Boet R, Mee E. Magnesium sulfate in the management of patients with Fisher Grade 3 subarachnoid hemorrhage: a pilot study. Neurosurgery. 2000 Sep;47(3):602-6; discussion 606-7.</citation>
    <PMID>10981747</PMID>
  </reference>
  <reference>
    <citation>Boet R, Poon WS, Chan MT. Re: Magnesium: a useful adjunct in the prevention of cerebral vasospasm following aneurysmal subarachnoid haemorrhage. J Clin Neurosci. 2003 May;10(3):394.</citation>
    <PMID>12763359</PMID>
  </reference>
  <reference>
    <citation>Wong GK, Poon WS, Chan MT, Boet R, Gin T, Lam CW. The effect of intravenous magnesium sulfate infusion on serum levels of sodium and potassium in patients with aneurysmal subarachnoid hemorrhage. Magnes Res. 2007 Mar;20(1):37-42.</citation>
    <PMID>17536487</PMID>
  </reference>
  <results_reference>
    <citation>Boet R, Chan MT, Poon WS, Wong GK, Wong HT, Gin T. Intravenous magnesium sulfate to improve outcome after aneurysmal subarachnoid hemorrhage: interim report from a pilot study. Acta Neurochir Suppl. 2005;95:263-4.</citation>
    <PMID>16463861</PMID>
  </results_reference>
  <results_reference>
    <citation>Wong GK, Chan MT, Boet R, Poon WS, Gin T. Intravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: a prospective randomized pilot study. J Neurosurg Anesthesiol. 2006 Apr;18(2):142-8.</citation>
    <PMID>16628069</PMID>
  </results_reference>
  <results_reference>
    <citation>Wong GK, Chan MT, Poon WS, Boet R, Gin T. Magnesium therapy within 48 hours of an aneurysmal subarachnoid hemorrhage: neuro-panacea. Neurol Res. 2006 Jun;28(4):431-5. Review.</citation>
    <PMID>16759446</PMID>
  </results_reference>
  <results_reference>
    <citation>Wong GK, Chan MT, Boet R, Poon WS. Correspondence to 'dose evaluation for long-term magnesium treatment in aneurysmal subarachnoid haemorrhage'. J Clin Pharm Ther. 2006 Aug;31(4):407.</citation>
    <PMID>16882114</PMID>
  </results_reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2005</study_first_submitted>
  <study_first_submitted_qc>July 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2005</study_first_posted>
  <last_update_submitted>December 21, 2009</last_update_submitted>
  <last_update_submitted_qc>December 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>George KC WONG</name_title>
    <organization>Division of Neurosurgery, The Chinese University of Hong Kong</organization>
  </responsible_party>
  <keyword>subarachnoid hemorrhage</keyword>
  <keyword>magnesium sulfate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

